患有细胞癌和类细胞脱差异化 (ARON-1研究) 患者免疫组合的临床特征和反应
Chiara Ciccarese1, Thomas Büttner2, Linda Cerbone3
1Medical Oncology Unit, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.
International journal of cancer
|September 7, 2024
概括
具有类特征的转移性细胞癌 (sRCC) 显示出侵略性行为. 基于免疫疗法的组合改善了sRCC患者的结果,无论它与其他免疫疗法或氨酸激酶抑制剂相结合.
科学领域:
- 在瘤学瘤学.
- 生殖尿道癌症 生殖尿道癌症
- 医疗治疗 医疗治疗
背景情况:
- 转移性细胞癌 (mRCC) 具有类特征 (sRCC) 与侵袭性瘤生物学和不良预后有关.
- 基于一线免疫疗法 (IO) 的组合已在清晰细胞RCC中显示出改善的结果,包括具有类特征的病例.
- 关于sRCC一线管理的现实数据有限.
研究的目的:
- 研究接受一线IO基组合治疗的sRCC患者的临床特征和结果.
- 确定与非sRCC相比,sRCC的发病率和基线特征.
- 根据一线治疗策略 (IO+IO与IO+铁氨酸激酶抑制剂[TKI]) 来比较sRCC患者的结局.
主要方法:
- 对ARON-1研究群体的回顾性分析 (NCT05287464).
- 确定和比较sRCC和非sRCC患者子组之间的临床特征.
- 基于治疗方案的总生存 (OS) 和无进展生存 (PFS) 的评估.
主要成果:
- 该研究在1362名具有中等或较低IMDC风险的mRCC患者中确定了226名sRCC和1136名非sRCC患者.
- 无SRCC患者的平均寿命为26.8个月,而非SRCC患者的平均寿命为35.3个月 (p=0.013).
- 在SRCC患者中,IO+TKI和IO+IO治疗组之间没有观察到中位数OS (34.4 vs. 26.4个月) 或PFS (12.4 vs. 12.3个月) 的显著差异.
结论:
- 证实sRCC是具有不良预后的侵袭性瘤.
- 基于IO的第一线组合可以提高sRCC患者的生存结果.
- 在IO+IO和IO+TKI一线策略之间的选择不会显著影响sRCC患者的结果.
更多相关视频
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
33.6K
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
14.5K
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Cytotoxic T Cells-mediated Immune Response
861
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
861
